









市场行情
/
股票
/
nasdaq-beam
/

Beam Therapeutics Inc

BEAM

34.351USD

+6.801+24.69%

交易中（美东）报价延迟15分钟

3.48B总市值

亏损市盈率 TTM



Beam Therapeutics Inc

34.351

+6.801+24.69%

概览公司财务分析

概览

公司

财务

分析

关于 Beam Therapeutics Inc 公司

Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype).

Beam Therapeutics Inc简介



公司代码BEAM

公司名称Beam Therapeutics Inc

上市日期Feb 06, 2020

CEOEvans (John M)

员工数量483

证券类型Ordinary Share

年结日Feb 06

公司地址238 Main Street

城市CAMBRIDGE

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编02142

电话18573278775

网址https://beamtx.com/

公司代码BEAM

上市日期Feb 06, 2020

CEOEvans (John M)

Beam Therapeutics Inc公司高管



名称

名称/职务

职务

持股

持股变动

Dr. Giuseppe Ciaramella, Ph.D.

President

107.78K

-7434.00%

Dr. Amy Simon, M.D.

Chief Medical Officer

1.74K

-67260.00%

Mr. John M. Evans

Chief Executive Officer, Principal Accounting Officer, Director

Mr. Graham K. Cooper

Independent Director

Dr. Mark C. Fishman, M.D.

Lead Independent Director

Dr. Carole Ho, M.D.

Independent Director

Ms. Kathleen E. Walsh

Independent Director

Dr. John M. Maraganore, Ph.D.

Independent Director

Dr. Christine P. Bellon, Ph.D.

Chief Legal Officer and Secretary

Ms. Christi Shaw

Independent Director

名称

名称/职务

职务

持股

持股变动

Dr. Giuseppe Ciaramella, Ph.D.

President

107.78K

-7434.00%

Dr. Amy Simon, M.D.

Chief Medical Officer

1.74K

-67260.00%

Mr. John M. Evans

Chief Executive Officer, Principal Accounting Officer, Director

Mr. Graham K. Cooper

Independent Director

Dr. Mark C. Fishman, M.D.

Lead Independent Director

Dr. Carole Ho, M.D.

Independent Director

收入明细

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

由于公司未披露，未能获取相关数据

地区USD

名称

营收

占比

United States

9.70M

0.00%

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 11月16日周日

持股股东

股东类型

持股股东

占比

Fidelity Management & Research Company LLC

11.11%

ARK Investment Management LLC

10.88%

Farallon Capital Management, L.L.C.

9.92%

The Vanguard Group, Inc.

9.09%

BlackRock Institutional Trust Company, N.A.

6.68%

其他

52.33%

持股股东

占比

Fidelity Management & Research Company LLC

11.11%

ARK Investment Management LLC

10.88%

Farallon Capital Management, L.L.C.

9.92%

The Vanguard Group, Inc.

9.09%

BlackRock Institutional Trust Company, N.A.

6.68%

其他

52.33%

股东类型

持股股东

占比

Investment Advisor

56.43%

Investment Advisor/Hedge Fund

20.11%

Hedge Fund

16.85%

Venture Capital

4.79%

Research Firm

2.41%

Individual Investor

1.27%

Bank and Trust

1.22%

Pension Fund

0.28%

Family Office

0.06%

机构持股



更新时间: 12月8日周一

报告期

机构数

持股数

持股占比

持股变动

2025Q4

532

103.69M

102.18%

-12.40M

2025Q3

555

103.63M

115.87%

-3.47M

2025Q2

543

105.59M

104.59%

+6.88M

2025Q1

544

98.62M

86.09%

+12.05M

2024Q4

527

78.89M

102.08%

+2.21M

2024Q3

525

76.92M

104.62%

-27.93K

2024Q2

525

76.91M

100.89%

+164.00K

2024Q1

537

75.04M

97.79%

-4.82M

2023Q4

537

73.96M

95.46%

+409.36K

2023Q3

543

73.50M

97.66%

+2.85M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Fidelity Management & Research Company LLC

11.27M

11.11%

-1.26M

-10.04%

Sep 30, 2025

ARK Investment Management LLC

11.04M

10.88%

+628.70K

+6.04%

Sep 30, 2025

Farallon Capital Management, L.L.C.

10.06M

9.92%

+50.00K

+0.50%

Sep 30, 2025

The Vanguard Group, Inc.

9.23M

9.09%

-459.51K

-4.74%

Sep 30, 2025

BlackRock Institutional Trust Company, N.A.

6.78M

6.68%

+54.70K

+0.81%

Sep 30, 2025

Amova Asset Management Co., Ltd.

4.83M

4.76%

+101.29K

+2.14%

Sep 30, 2025

ARCH Venture Partners

4.54M

4.47%

Sep 30, 2025

State Street Investment Management (US)

4.01M

3.95%

+370.39K

+10.18%

Sep 30, 2025

Bellevue Asset Management AG

2.89M

2.85%

Sep 30, 2025

Kynam Capital Management LP

2.52M

2.48%

+100.00K

+4.14%

Sep 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

ARK Genomic Revolution ETF

4.45%

Global X Genomics & Biotechnology ETF

2.42%

ARK Innovation ETF

2.3%

WisdomTree BioRevolution Fund

2.13%

Virtus LifeSci Biotech Clinical Trials ETF

0.97%

Franklin Genomic Advancements ETF

0.96%

State Street SPDR S&P Biotech ETF

0.84%

Harbor Health Care ETF

0.53%

Direxion Daily S&P Biotech Bull 3X Shares

0.51%

iShares Health Innovation Active ETF

0.3%

ARK Genomic Revolution ETF

占比4.45%

Global X Genomics & Biotechnology ETF

占比2.42%

ARK Innovation ETF

占比2.3%

WisdomTree BioRevolution Fund

占比2.13%

Virtus LifeSci Biotech Clinical Trials ETF

占比0.97%

Franklin Genomic Advancements ETF

占比0.96%

State Street SPDR S&P Biotech ETF

占比0.84%

Harbor Health Care ETF

占比0.53%

Direxion Daily S&P Biotech Bull 3X Shares

占比0.51%

iShares Health Innovation Active ETF

占比0.3%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

Beam Therapeutics Inc的前五大股东是谁？



Beam Therapeutics Inc 的前五大股东如下：
Fidelity Management & Research Company LLC持有股份：11.27M，占总股份比例：11.11%。
ARK Investment Management LLC持有股份：11.04M，占总股份比例：10.88%。
Farallon Capital Management, L.L.C.持有股份：10.06M，占总股份比例：9.92%。
The Vanguard Group, Inc.持有股份：9.23M，占总股份比例：9.09%。
BlackRock Institutional Trust Company, N.A.持有股份：6.78M，占总股份比例：6.68%。